Table 3.
Demographic characteristics
|
Parameter
a
|
Cyclosporine + MMF |
Tacrolimus + EC-MPS |
P value |
|---|---|---|---|
| (n = 30) | (n = 28) | ||
| Age (years) |
52.3 ± 9.29 |
54.1 ± 11.5 |
0.527b |
| Time post-transplant (years) |
6.93 ± 4.27 |
5.15 ± 3.34 |
0.084b |
| Male |
30 (100%) |
13 (46.4%) |
<0.001* |
| Caucasian |
17 (56.7%) |
13 (46.4%) |
0.221c |
| BMI (kg/m2) |
33.1 ± 6.73 |
30.4 ± 6.94 |
0.151b |
| eGFR (ml/min/1.73 m2) |
51.7 ± 13.5 |
52.2 ± 18.7 |
0.921b |
| Albumin |
4.24 ± 0.37 |
4.26 ± 0.41 |
0.839b |
| WBC (cells/mm3) |
6.81 ± 2.26 |
6.38 ± 1.52 |
0.401b |
| MPA dosee |
1417 ± 407 |
1242 ± 319 |
0.048d* |
| Prednisone use |
12 (40.0%) |
9 (32.1%) |
0.585 c |
| Calcineurin inhibitor trough concentration (ng/ml) | 124 ± 47.1 | 6.80 ± 1.98 | NA |
aData presented as mean ± standard deviation or frequency (percentage); bT test; c Chi-square test; dWilcoxon test; eExpressed as active mycophenolic acid.
*p ≤ 0.05: statistical significance.
BMI, body mass index; eGFR, estimated glomerular filtration rate; MMF, mycophenolate mofetil; MPA, mycophenolic acid; EC-MPS, enteric coated mycophenolate sodium; NA, not applicable; WBC, white blood cells.